EUCTR2005-005666-36-SE进行中（未招募）不适用
ow-dose Cytotoxics as Anti-angiogenesis Treatment” following AdjuvantInduction Chemotherapy for Patients with ER-negative and PgR-negativeBreast CancerMaintenance Chemotherapy in Hormone Non- Responsive Breast Cancer - Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer
International Breast Cancer Study Group0 个研究点目标入组 1,080 人开始时间: 2009年7月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,080
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Premenopausal or postmenopausal patients with histologically proven primary breast cancer.
- •The primary tumor must be classified as T1a,b,c, T2, T3, or pT4 with minimal dermal invasion, Nx, pN0, pSentN0, pN1, or pN2, and M0. Patients with disease defined as SNB positive are eligible only if they have undergone an axillary dissection, OR are SNB micrometastatic and are randomized to IBCSG Trial 23-01. The tumor must be confined to the breast, without detected metastases elsewhere.
- •Estrogen and progesterone receptor status must be known by immunohistochemistry, before randomization, and both must be negative, which is defined as < 10% of the tumor cells positive by immunohistochemical evaluation.
- •HER2 status must be known and determined by either immunohistochemistry or FISH before randomization.
- •The induction chemotherapy must be approved by the IBCSG Scientific Committee and must begin (or have begun) within 8 weeks of definitive surgery.
- •Patients must have had either:
- •a total mastectomy. Radiotherapy is optional after mastectomy. OR
- •a breast-conserving procedure (lumpectomy, quadrantectomy or partial mastectomy with negative margins) with radiotherapy planned. Radiation therapy to the conserved breast is required.
- •Patient must have had pathological axillary staging performed on a specimen from axillary clearance or sentinel node biopsy. In order to be classified as pN0, patients who receive axillary clearance must have a minimum of 6 lymph nodes available for pathological examination.
- •Patients must have completed pre-randomization Quality of Life (QL) Forms. The only
- •exceptions are cognitive or physical impairment that interferes with QL assessment or inability to read any of the languages available on IBCSG QL forms.
- •The patient must be in adequate health to begin or continue with induction chemotherapy or start maintenance chemotherapy:
- •WBC greater than 3.0x109/l
- •Platelets greater than 100x109/l
- •Serum creatinine below 120 µmol/l, adequate liver values
- •Serum bilirubin below 20 µmol/l
- •No cystitis
- •No evidence of any toxicity grade 2 or worse (CTC), in particular: nausea, vomiting,
- •diarrhea, mucositis (stomatitis or any other mucousal inflammation), or epigastric pain.
- •Written informed consent dated and signed by both patient and investigator.
- •Must be geographically accessible for follow-up.
- •Patients must be informed of, and agree to, data and material transfer and handling, in accordance with national data protection guidelines and Swiss data protection law (as IBCSG is a foundation under Swiss law).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with T4 carcinoma with ulceration of skin, infiltration of skin (except pathologically minimal dermal involvement), peau d'orange or inflammatory breast cancer, or with distant metastases. Any suspicious manifestation requires appropriate investigation to exclude metastasis.
- •Patients with bilateral malignancies (except in situ carcinoma), or with a suspicious mass in the opposite breast, unless that mass has been proven by biopsy to be benign.
- •Patients, who, before start of induction chemotherapy, had a skeletal pain of unknown cause, elevated alkaline phosphatase, or a bone scan showing hot spots for which metastases cannot be ruled out by X-ray, MRI and/or CT.
- •Patients in whom the margins of the resected specimen (whether mastectomy or local excision) contained invasive tumor. Patients who have local excision with a positive margin may become eligible if within 8 weeks from first surgery they undergo adequate resection or mastectomy with clear margins.
- •Patients with previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix, or contra- or ipsilateral in situ breast carcinoma.
- •Patients who have received prior therapy for breast cancer other than primary irradiation, approved induction regimen, or trastuzumab. Prior endocrine therapy for breast cancer or prevention is not permitted.
- •Patients with non-malignant systemic diseases that would prevent them from undergoing any of the treatment options, or would prevent prolonged follow-up.
- •Patients with psychiatric or addictive disorders that would prevent them from giving informed consent to therapy and randomization.
- •Patients who either have been pregnant or who have lactated within 6 months of diagnosis.
- •Patients with a history of noncompliance to medical regimens and patients who are considered potentially unreliable.
研究者
相似试验
已完成
3 期
Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast CancerBreast CancerNCT00022516ETOP IBCSG Partners Foundation1,086
进行中（未招募）
不适用
Antiangiogenic Treatment of Advanced or Metastatic Hepatocellular Cancer (HCC) - An open label, stratified, single-arm phase II study of Bevacizumab and RAD001EUCTR2007-005422-76-DEPD Dr. Gerhard Treiber
终止
2 期
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast CancerChemotherapyBreast Cancer, MetastaticNCT01067989HaEmek Medical Center, Israel22
进行中（未招募）
不适用
Effect of angiogenesis inhibiting therapy in patients progressing on endocrine treatment and patients with triple negative breast cancer - a translational phase II study within theSwedish Association of Breast Oncologists SABO-2010-01Patients with breast cancer who are oestrogen receptor positive but HER2 negative and progressing on endocrine therapy. Patients with locally advanced or recurrent triple negative breast cancer (TNBC) can also be included. Patients with TNBC will not receive endocrine therapy.MedDRA version: 14.1Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022065-10-SESahlgrenska University Hospital
已完成
2 期
Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian CancerPlatinum-resistant Advanced Ovarian CancerNCT01262014Grupo Español de Investigación en Cáncer de Ovario28